<div id="readability-page-1">OLN324 has shown significantly quicker and more substantial enhancements in anatomic results in patients with diabetic macular edema (DME), along with slightly higher visual improvements that were maintained throughout 20 weeks. This was achieved with fewer follow-up treatments when compared to faricimab. Recent anatomical data indicates that OLN324 effectively achieves faster, greater, and longer-lasting improvements in DME patients.</div>

RHHBY

RHHVF

<p>OLN324 has shown significantly quicker and more substantial enhancements in anatomic results in patients with diabetic macular edema (DME), along with slightly higher visual improvements that were maintained throughout 20 weeks. This was achieved with fewer follow-up treatments when compared to faricimab. Recent anatomical data indicates that OLN324 effectively achieves faster, greater, and longer-lasting improvements in DME patients.</p>

Unusual Whales

Roche

ROCHE HOLDINGS AG

SPDR S&P Biotech

Adma Biologics

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema